By Fineline Cube GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.
Clinical Trial Outcomes Summary
| Trial | Dose Regimen | Primary Endpoint | Result | Timepoint |
|---|---|---|---|---|
| CALM-1 | Camlipixant 50mg BID | 24-hour cough frequency reduction vs placebo | Met (statistically significant) | Week 12 |
| CALM-2 | Camlipixant 50mg BID | 24-hour cough frequency reduction vs placebo | Not met (not statistically significant) | Week 24 |
| Both Trials | Camlipixant 25mg BID | 24-hour cough frequency reduction vs placebo | Not met (not statistically significant) | Weeks 12/24 |
| Both Trials | Both doses | Chronic Cough Diary (CCD) secondary endpoints | Not met (failed to reach target thresholds) | Various |
Drug Profile & Development Context
- Molecule: Camlipixant – selective P2X3 receptor antagonist
- Indication: Refractory chronic cough (RCC) – persistent cough lasting >8 weeks despite standard treatment
- Mechanism: Blocks P2X3 receptors involved in cough reflex hypersensitivity
- Development Stage: Phase III (pivotal trials completed)
- Competitive Landscape: Part of emerging class of P2X3 antagonists targeting chronic cough, following precedents like gefapixant
Safety Profile Assessment
| Parameter | Camlipixant | Placebo | Assessment |
|---|---|---|---|
| Overall AE Incidence | Similar | Similar | Favorable safety profile |
| Treatment-Related AE Severity | Similar | Similar | No significant safety concerns |
| Discontinuation Rate | Not disclosed | Not disclosed | Requires further analysis |
| Taste-Related AEs | Not specifically reported | Not specifically reported | Key differentiator vs other P2X3 antagonists |
Strategic Implications & Next Steps
- Regulatory Pathway: Mixed results create uncertainty for regulatory submissions; GSK may need to conduct additional analyses or trials
- Commercial Viability: Failure of key secondary endpoints (CCD measures) and inconsistent primary endpoint results across trials weaken value proposition
- Market Opportunity: Refractory chronic cough affects an estimated 5-10 million adults in major markets, representing significant unmet need
- Competitive Positioning: Results less compelling than earlier P2X3 antagonist data, potentially limiting market differentiation
- Investment Impact: Likely negative near-term impact on GSK’s respiratory pipeline valuation; company may reassess development priorities
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial prospects for camlipixant. Actual outcomes may differ due to risks including regulatory decisions, competitive dynamics, and further data analysis.-Fineline Info & Tech